About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: February 2011
TWANK REDUX – Bigger and Better
Where do you stand in your Twitter Ranking? In early January, I ran a posting that was quite popular that provided pharmaceutical twitter rankings – or TWANK as I called it. The list included every pharma twitter feed of which … Continue reading
Posted in New and Social Media
2 Comments
Weekly Roundup – February 11, 2011
It is a flu season that has seemed endless. Comfort food is only providing so much comfort. Highly huggable puppies have been most helpful. Awash in tea. Help. Meanwhile, here are a few of the more interesting things than flu … Continue reading
Posted in Weekly Roundup
1 Comment
House Appropriations Proposes Specific Cuts for the Continuing Resolution
Yesterday morning I posted about impending budget cuts to FDA for the next fiscal year and posed the question whether or not less money might equate to less enforcement. Ironically, a short time later, the House Appropriations Committee released a … Continue reading
Posted in Legislation, Proposed Legislation
2 Comments
Will Less Funding for FDA Result in Less Enforcement?
From time to time on this blog, I have raised the question about whether the growth trajectory of the FDA is sustainable. Already overseeing the regulation of over one-quarter of the economy, within the past few years, the mandate of … Continue reading
Posted in FDA Policy, Politics
1 Comment
Pharma and FDA Twitter Tips
Sorry again for the lack of posts the past week. If you flu-shot advocates would like to say “I told you so” please feel free…. Some people like lists. Some don’t. I am a fence-sitter. But I certainly don’t like … Continue reading
Posted in New and Social Media
4 Comments